#### **Overview** Blue Jet Healthcare Limited is a science-driven specialty pharmaceutical company operating under a **Contract Development and Manufacturing Organization (CDMO)** model, specializing in **contrast media intermediates**, **high-intensity sweeteners**, and **pharmaceutical intermediates and APIs**. With over two decades of experience, the company has established itself as a trusted global supplier to leading innovator pharmaceutical and FMCG companies. It leverages deep **advanced chemistry capabilities**, regulatory compliance, and long-term customer relationships to deliver complex molecules across critical therapeutic and consumer health segments. The company’s strategic focus on **forward and backward integration**, **R&D-led innovation**, and **scalable manufacturing infrastructure** positions it as a key player in niche, high-barrier markets with limited global competition. --- ### **Core Business Segments** 1. **Contrast Media Intermediates (CMI) – 68% of FY24 Revenue** - **Primary Products:** Key starting materials (KSMs) and advanced intermediates for **iodinated (X-ray/CT)** and **gadolinium-based (MRI)** contrast agents. - **Customers:** Supplies three of the world’s largest contrast media manufacturers: **GE Healthcare, Guerbet, and Bracco**. - **Market Position:** - Dominant Indian exporter (>75% of India’s exports) of the key intermediate *5-Amino-N,N'-bis(2,3-dihydroxypropyl)isophthalamide*. - Accountable for ~67.7% of FY24 revenue and growing through value chain migration. - **Value Chain Expansion:** - From **1 key intermediate in 2000** → **19 advanced intermediates by FY25**. - Commercialized **Gadopiclenol intermediate** and scaled new iodinated intermediates (to launch FY2026). - Building a **dual-platform pipeline** for iodinated and gadolinium-based agents. - **Capacity & Strategy:** - Quadrupled CMI capacity in recent years. - ~70% of CMI revenue secured via **multi-year supply agreements**, often involving co-development and regulatory collaboration. - Backward integration project underway at **Unit III, Mahad**, to produce a critical imported feedstock, reducing forex risk and improving margins. 2. **High-Intensity Sweeteners (HIS) – 18–20% of Revenue** - **Primary Products:** **Saccharin** and its salts (sodium saccharin, calcium saccharin). - **Applications:** FMCG (beverages, tabletop sweeteners), pharmaceuticals, oral care, agrochemicals, animal nutrition. - **Customers:** Global leaders including **Colgate-Palmolive (India) Ltd** and **Unilever**. - **Scale & Competitiveness:** - **10% of global saccharin capacity** (3,500–4,000 MT/year). - Serves **>300 customers** across regulated markets. - Fully backward-integrated with zero by-products, USP/FCC/EP/BP/E954 compliant. - **Financials:** - ₹1,335.1 crore revenue in FY25. - 7.8% CAGR over last four years; strong retention, no major account losses. - **Innovation:** - Launched **calcium saccharin** to meet customer-specific formulations. - Focus on **taste consistency and quality** in a “sticky” FMCG supply chain. 3. **Pharma Intermediates & APIs (PI/API) – 13–14% of Revenue** - **Therapeutic Focus:** Chronic diseases – **cardiovascular (CVS), oncology, central nervous system (CNS)**. - **Clients:** Innovator pharma firms and multinational generics. - **Recent Milestones:** - **>4x YoY revenue growth in FY2025**, driven by commercial-scale supply of a **non-statin oral drug** approved in the US, Europe, Japan, and LatAm for primary and secondary cardiovascular indications. - **R&D Pipeline:** - Developing **four APIs**: two in oncology, one in CVS, one in CNS. - Supplies intermediates for **four patented drugs**, including late-stage molecules in NCE pipelines. - **Strategic Advantage:** - Leverages **sweeteners business relationships** to expand into adjacent pharma domains. - Focus on **import substitution in India** and niche chronic illness therapies. --- ### **Manufacturing & Infrastructure** - **Current Facilities (Maharashtra):** - **Shahad (Unit I):** 200.6 KL capacity. - **Ambernath (Unit II):** 607.3 KL (expanded with 157 KL in FY2024–25; Plant 6 operational). - **Mahad (Unit III):** 141.4 KL, with multi-purpose plant and backward integration project under development. - **Total Reaction Capacity:** ~**1,020.90 KL** (as of Q4 FY24). - **Future Expansion:** - **Unit IV (Ambernath, Morivali):** Greenfield site; effluent plant complete, commercial ops expected by **end of FY2026**. - **102.48-acre Land Acquired in Andhra Pradesh:** To build a new facility with **1,000 KL capacity (Phase I by FY2028)**, enhancing global CDMO reach. - **Mahad Multipurpose Plant (MPP):** - ~30 reactors, GMP-compliant, cleanrooms. - Supports **kilos to multi-tons** production; CAPEX increased to ₹300 crores. - Operational in **H2 FY2027**. - **Efficiency & Sustainability:** - Modular, **semi-automated** processes (e.g., hydrogenation, continuous flow synthesis). - Designed for **solvent recovery**, **waste reduction**, **minimal changeover downtime**. - 60–65% overall capacity utilization, with **significant operational headroom**. --- ### **R&D & Technology Leadership** - **R&D Center:** - **BlueJet Advance Research Centre (BARC)** at Ambernath, Unit II: - >75 scientists, including PhDs in organic chemistry. - DSIR-recognized; drives **process optimization, scale-up, and product development**. - **New R&D Centre (Hyderabad):** ~₹40 crores investment, focused on: - **Peptides, GLP-1 intermediates, enzymatic synthesis, immobilized biocatalysis**. - Amino acid derivatives for chronic disease pipelines. - Rapid turnaround for **virtual biotech RFPs**. - **Recent Capabilities Added:** - **Enzymatic synthesis**, **pyrophoric chemistry**, **iodination**. - Patents filed in **green chemistry/enzymatic processes**; first enzymatic product expected FY2026. - **Chiral selection via enzymatic chemistry** in cardiovascular molecule, offering efficiency edge. - **Innovation Pipeline:** - ~20 R&D opportunities tracked; ~6 in **late Phase III or commercial stage**. - Developing **45+ peptide fragments** for commercial readiness. - Focus on **NCEs, patented drugs, and niche generics** with global innovators. --- ### **CDMO Business Model & Customer Strategy** - **Operating Framework:** **Collaboration, Development, Manufacturing (CDMO)**. - Engages from **early clinical development** through **commercial launch**. - **Customer Mix:** - **~400+ global customers** across **16+ countries** (North America, Europe, Asia, LatAm). - Export share: ~**87% of revenue**, primarily to **regulated markets (US, EU)**. - Long-term relationships: **4 to 26 years** with top contrast media players. - **Revenue Visibility:** - ~70% of sales backed by **annual/multi-year contracts**. - Products **qualified, approved, validated**, ensuring low churn. - **Diversification Efforts:** - Reducing customer concentration; expanding into **oncology, CNS, cardiovascular products**, and **GLP-1 intermediates**. - Targeting **biosimilars** as patents expire (from 2026), capitalizing on rising demand. --- ### **Financial Performance (FY2025 Highlights)** | Metric | Value (INR) | Growth / Margin | |----------------------------|--------------------|-------------------------| | **Revenue** | ₹10,300 million | **+45% YoY** | | **EBITDA Margin** | 37% | Stabilized | | **Profit After Tax (PAT)** | ₹3,052 million | **+86% YoY** | | **Fixed Assets Turnover** | 5.13x (FY24) | High efficiency | | **ROE (FY24)** | 21.45% | Strong shareholder return | **Recent Growth Drivers:** - Launch of **cardiovascular intermediate** with blockbuster potential. - Increased production in contrast media (MRI/NCEs). - Expansion in sweeteners with **calcium saccharin** launch.